Ketamine for Panic Attacks: How It Works and What to Expect

Can Ketamine Therapy Help With Panic Attacks?

Panic attacks are sudden surges of intense fear accompanied by physical symptoms like a racing heart, shortness of breath, and derealization. Panic disorder is a distinct clinical diagnosis characterized by recurrent attacks and persistent anticipatory anxiety about future episodes.

Clinical evidence and case literature suggest ketamine may meaningfully reduce panic symptoms. The following subsections break down what that evidence looks like and who may be a candidate.

What Research Says About Ketamine for Panic Symptoms

A notable case report described a patient with severe panic disorder, agoraphobia, and generalized anxiety who achieved sustained symptom resolution following a single ketamine infusion.⁶

While case reports are hypothesis-generating rather than definitive, they provide important clinical signals. Broader anxiety research further supports these findings.

A randomized, placebo-controlled crossover trial for social anxiety disorder demonstrated significant anxiety symptom reduction compared to placebo.⁷ This is highly relevant to panic disorder because both conditions share overlapping neural substrates and fear processing mechanisms.

Building on decades of clinical research, Mindbloom has published real-world outcomes data on at-home ketamine therapy. In a peer-reviewed study of 11,441 Mindbloom clients, 89% reported improvement in their anxiety symptoms.¹

This study also found a 56.1% response rate, measured using the GAD-7 assessment tool. Individual results may vary.

While panic-disorder-specific randomized controlled trials are still needed, the current evidence provides a substantive clinical rationale. The convergence of case evidence, controlled anxiety trials, and large-scale outcomes data supports its use.

When Ketamine May Be Considered for Panic Attacks

Ketamine therapy may be appropriate for adults experiencing recurrent panic attacks, particularly those with co-occurring mental health conditions. It is often considered for people who have not achieved adequate relief from traditional daily medications.

Many patients explore this option after finding limited success with SSRIs, SNRIs, benzodiazepines, or cognitive behavioral therapy (CBT) alone. It also offers an option for individuals seeking faster-acting relief than traditional daily medications typically provide.

Eligibility for ketamine therapy is always determined through a comprehensive clinical assessment, not self-selection. A licensed clinician evaluates your medical history, psychiatric history, current medications, and cardiovascular health before prescribing.

Ketamine is an evidence-based option that may be particularly well-suited for certain clinical profiles. It is not exclusively a last-resort treatment.

Clinical profiles often considered for treatment:

• Co-occurring conditions: You experience panic alongside depression, PTSD, or generalized anxiety.
• Inadequate prior response: You have found limited relief from SSRIs, SNRIs, benzodiazepines, or psychotherapy alone.
• Desire for faster onset: You are seeking quicker relief, as traditional antidepressants may take weeks to work.
• Clinical screening required: Your eligibility is always determined by a licensed clinician, not self-assessed.

How Ketamine May Help With Panic Attacks

Ketamine's primary mechanism of action involves modulating glutamate signaling via NMDA receptors in the brain. This process promotes synaptogenesis and neuroplasticity.

Neuroplasticity is the brain's ability to form new neural connections and reorganize existing ones to adapt to new experiences. Panic attacks involve hyperactivation of the amygdala, the brain's threat-detection center, alongside weakened regulatory input from the prefrontal cortex.

Over time, repeated panic attacks create entrenched fear circuits that fire inappropriately. Ketamine's neuroplastic effects may help restore balance between these regions by strengthening prefrontal regulation and dampening amygdala overreactivity.

This glutamate-driven, neuroplasticity-based mechanism is why ketamine can produce rapid changes in anxiety and fear processing. It is mechanistically distinct from how SSRIs or benzodiazepines work.

Because it addresses structural neural wiring, its effects may extend well beyond the dosing session itself. This is especially true when the medicine is paired with integration practices.

What Happens in the Brain During a Panic Attack

During a panic attack, the amygdala detects a perceived threat even when no real physical danger exists. This triggers the sympathetic nervous system, releasing adrenaline and initiating a fight-or-flight response.

How Ketamine Targets Those Pathways

Ketamine temporarily modulates NMDA receptor activity, which increases glutamate release in the brain. This triggers a biological cascade that promotes the growth of new synaptic connections, a process known as synaptogenesis.

This activity is particularly concentrated in the prefrontal cortex, helping to restore its ability to regulate fear responses. This process opens a neuroplastic window, allowing the brain to form new patterns of responding to perceived threats.

Instead of defaulting to the entrenched panic circuit, your brain can develop healthier coping mechanisms. Integration practices like reflection, journaling, and coaching during this window can help consolidate these new neural pathways.

This approach differs fundamentally from traditional psychiatric medications. SSRIs gradually modulate serotonin over weeks, while benzodiazepines enhance GABA signaling for acute relief without addressing underlying neural patterns.

Ketamine's mechanism addresses the structural wiring of fear circuitry, not just the chemical signaling.

How Quickly Ketamine Can Work for Panic Symptoms?

Many people report noticeable symptom improvement within hours or days of their first ketamine session. This rapid onset is one of ketamine's most distinctive clinical features compared to traditional psychiatric medications.

Acute effects during and immediately after a session may include reduced anxiety, a shift in perspective, or profound emotional relief. However, more durable and cumulative benefits typically develop over a clinician-guided series of sessions.

This long-term benefit includes a potential reduction in the frequency and intensity of future panic attacks. Speed of onset is a meaningful benefit, but lasting change is the ultimate clinical goal.

A single session may provide rapid relief, while a defined treatment framework supports durable outcomes. Treatment frequency is personalized based on clinical guidance and individual response.

Rapid Symptom Changes

After a first session, individuals may notice a reduced intensity of anxious thoughts or a sense of emotional distance from their usual fear triggers. Some experience deep physical relaxation or a sudden shift in perspective on recurring worries.

Experiences vary widely, with some people noticing changes the same day and others within a few days. This rapid onset is directly linked to ketamine's glutamate-driven mechanism.

Because it promotes immediate synaptogenesis, it operates on a fundamentally different timeline than serotonin-based medications. Many people report noticeable changes quickly, though clinical response is typically evaluated across a full treatment protocol.

How Long Relief Can Last Across a Treatment Series

The effects of a single ketamine session may last for days to weeks, with significant variability between individuals. A protocol-driven series of sessions is designed to build cumulative benefit and more durable change over time.

The neuroplastic window opened by each session builds upon the previous one. Integration practices are what help translate acute symptom relief into lasting improvement.

Journaling, coaching, reflection, and intentional behavioral changes during the neuroplastic window help consolidate new neural pathways. Some people benefit from periodic follow-up sessions to maintain their progress.

Treatment frequency is always clinician-guided based on individual response and therapeutic goals. It does not rely on fixed intervals.

Panic Attacks vs. Broader Anxiety: What the Evidence Covers

Panic attacks and panic disorder are clinically distinct from other anxiety conditions like generalized anxiety disorder, social anxiety disorder, and PTSD. While they share overlapping symptom profiles and neural substrates, they have different diagnostic criteria. The strongest controlled evidence for ketamine comes from studies on social anxiety disorder, treatment-resistant depression with comorbid anxiety, and broader anxiety symptom measures.

Panic-disorder-specific controlled trials are currently limited, though published case evidence is highly positive. PTSD-related anxiety also has a robust evidence base.

In a real-world analysis of 374 Mindbloom PTSD program completers, 92.2% reported symptom improvement.³ This preprint study also showed a 79.7% response rate and a 60.7% remission rate, measured using the PCL-5.

Mindbloom's reported anxiety response rate of 56.1% is comparable to or exceeds response rates reported in selected psychotherapy trials for anxiety disorders.¹⁰ Mindbloom's reported anxiety response rate also exceeds response rates reported in selected SSRI and SNRI trials for generalized anxiety disorder.^{11, 12}

While direct comparisons across treatment modalities should be interpreted with caution due to differences in study design, patient populations, and outcome measures, these outcomes do provide valuable context. If you experience panic attacks alongside depression, PTSD, or generalized anxiety, the evidence base supporting ketamine therapy is broad and well-established.

Evidence landscape by condition:

• Social Anxiety Disorder: Randomized controlled trials show significant symptom reduction versus a placebo.
• Generalized Anxiety (GAD): Real-world outcomes show an 89% improvement rate and a 56.1% response rate on the GAD-7.
• PTSD-Related Anxiety: Preprint data shows a 79.7% response rate and a 60.7% remission rate on the PCL-5.
• Panic Disorder: Case reports document sustained resolution, though controlled trials remain limited.
• Depression with Comorbid Anxiety: Multiple randomized trials show consistent anxiety symptom reduction alongside depression improvement.

Ketamine Side Effects and Safety Risks

Like all medications, ketamine carries potential side effects and safety considerations. Understanding what these effects are, how common are they, and how they are managed is essential for informed decision-making.

Within clinician-supervised programs, side effects occur at known, manageable rates. Common acute effects include nausea, dizziness, fatigue, dissociation, and temporary blood pressure elevations, while less common concerns include oversedation or complications in higher-risk patients; clinical screening, individualized dosing, and monitoring are used to reduce these risks.

Mindbloom's published safety data demonstrates a highly favorable safety profile. In a study of 11,441 patients, side effects occurred in approximately 4 to 5% of sessions.¹

Serious adverse events occurred in fewer than 0.1% of sessions. The discontinuation rate due to adverse events was 0.4%.

Common Side Effects

Some people experience transient side effects during or shortly after a ketamine session. These effects are usually acute and time-limited because they track ketamine's active window, with symptoms such as nausea, dizziness, fatigue, or perceptual changes typically easing over the following hours as session effects wear off.

Most people find the dissociative state manageable or even meaningful within a guided setting. It is a known, often therapeutic aspect of the experience.

If the perceptual shift feels unfamiliar, preparation materials and the required peer treatment monitor can help you navigate it safely.

Common transient side effects:

• Nausea: Some people experience mild nausea during or shortly after a session, which typically resolves within hours.
• Dizziness or lightheadedness: This is related to temporary blood pressure changes and resolves as session effects subside.
• Dissociation: This is a temporary shift in perception of self or surroundings, often described as reflective within a guided setting.
• Temporary blood pressure increase: Ketamine has sympathomimetic properties, so cardiovascular screening during intake helps identify those at higher risk.
• Fatigue: Some people feel tired afterward, and the only universally consistent restriction is avoiding driving until after a full night of sleep.

Less Common but Serious Risks

Ketamine overdose can involve excessive sedation, respiratory depression, and loss of consciousness. This risk is primarily associated with unsupervised use, recreational dosing, or combination with central nervous system (CNS) depressants like alcohol or opioids.

Within clinical programs, dosing is sub-anesthetic and clinician-determined. A peer treatment monitor is also required to be present during every session to ensure safety.

Ketamine is classified as a Schedule III controlled substance, meaning it carries a risk of dependence and addiction. Dependence involves building tolerance and experiencing withdrawal symptoms upon cessation.

This risk is primarily documented in chronic, unsupervised recreational use patterns. Program safeguards include screening for substance use history, defined treatment durations, and ongoing clinician monitoring.

Long-term, high-frequency recreational use has been associated with bladder toxicity, known as interstitial cystitis, and cognitive effects.⁹ These risks are not characteristic of therapeutic use at sub-anesthetic doses within a clinically managed program.

Can Ketamine Cause or Worsen Panic Attacks?

While the unfamiliarity of dissociation could feel anxiety-provoking for some people without proper preparation, this is pharmacologically different from ketamine inducing a panic attack. Preparation materials, a safe environment, and the presence of a peer treatment monitor are specifically designed to reduce this risk.

The clinical oversight within a legitimate program is what distinguishes the therapeutic experience from uncontrolled contexts where anxiety is more likely.

Precautions and Contraindications

Eligibility for ketamine therapy is determined through a thorough clinical assessment, not self-selection. Certain medical and psychiatric conditions require careful evaluation by a prescribing clinician.

Ketamine therapy may not be appropriate for individuals with uncontrolled hypertension. This is why cardiovascular screening is a standard part of the intake process.

Active psychosis, serious cardiac or respiratory conditions, and pregnancy are also evaluated during the medical history review.

Key clinical screening areas:

• Uncontrolled hypertension: Your cardiovascular health is evaluated during intake.
• Active psychosis or psychotic disorders: These conditions require careful psychiatric evaluation.
• Serious cardiac or respiratory conditions: These are assessed during the medical history review.
• Pregnancy: Ketamine therapy is not appropriate during pregnancy.
• Substance use history: This is screened and evaluated as part of the eligibility assessment.
• Medication interactions: MAOIs, CNS depressants, and other medications are reviewed by the prescribing clinician.

What to Look for in a Legitimate Ketamine Therapy Program

Not all ketamine therapy is the same. The quality, safety, and effectiveness of treatment depend heavily on the clinical framework surrounding it, rather than just the medication itself.

A legitimate program provides comprehensive care that extends before, during, and after the dosing session. This includes thorough medical screening, preparation resources, and integration support to help translate acute experiences into lasting behavioral change.

The presence of these elements is what separates clinically responsible ketamine therapy from unstructured prescribing. When evaluating any provider, these are the critical components to look for.

Key elements of a legitimate program:

• Licensed clinician oversight: A prescribing clinician conducts a thorough evaluation, determines eligibility, sets dosing, and monitors progress.
• Preparation guidance: You receive support before the first session on what to expect, how to set intentions, and how to create a safe environment.
• In-session safety requirements: A peer treatment monitor must be present, with clear protocols for navigating the experience.
• Integration support: You have access to coaching, reflection, or therapeutic follow-up to help consolidate neuroplastic changes.
• Defined treatment programs: You follow a series of sessions with a clear beginning, middle, and end, rather than open-ended prescribing.
• Transparent safety data: The provider demonstrates a willingness to share published outcomes, side effect rates, and adverse event data.

What Mindbloom's At-Home Ketamine Therapy Includes

Mindbloom provides a specific, evidence-backed implementation of this clinical framework. The care model combines sub-anesthetic ketamine with comprehensive support to maximize safety and therapeutic outcomes.

Mindbloom's 6-session program is $215 per session, billed as $430 per month for three months, totaling $1,290. Each program includes clinician consults to evaluate eligibility, determine dosing, and monitor progress.

Sessions take place at home using sublingual tablets or subcutaneous injectables, with a required peer treatment monitor present. Mindbloom is the only at-home provider offering subcutaneous administration.

Clients also receive one-on-one guide coaching, unlimited Group Integration Circles, and unlimited guide messaging. The program includes a Bloombox experiential toolkit and full access to the Mindbloom App.

Building on decades of clinical research on ketamine's therapeutic applications, Mindbloom has published two of the largest peer-reviewed, real-world outcomes studies of at-home ketamine therapy to date.^1,2 Over 700,000 clinician-supervised sessions have been facilitated to date.

Disclaimer and Safety Information

IMPORTANT SAFETY INFORMATIONKetamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

OFF-LABEL USE DISCLOSUREKetamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.